Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2019-01-23 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Update on Cancer Research UK's Grand Challenge
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8229N' and is dated January 23, 2019. It discusses Scancell Holdings Plc providing an update regarding a Cancer Research UK Grand Challenge Award shortlisting, which is a general corporate announcement related to research progress and collaboration. The text concludes with contact information and a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory news service announcement. Since the content is a general update/news item that doesn't fit specific categories like ER, CT, or DIRS, the most appropriate classification is the general regulatory announcement fallback category.
2019-01-23 English
Appoints Heads of Research and Manufacturing
Board/Management Information Classification · 98% confidence The document begins with an 'RNS Number' and is dated January 21, 2019. The content announces the appointment of two senior personnel: Head of Research and Head of Manufacturing. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management change, making MANG the most specific classification. The document length is moderate, but the content is a specific announcement, not a general regulatory filing fallback.
2019-01-21 English
Scancell to Present at Two Conferences
Regulatory Filings Classification · 99% confidence The document starts with an 'RNS Number' and is dated November 12, 2018. The content announces that Scancell Holdings Plc will be presenting at two external industry events (LSX Inv€$tival Showcase and BioCentury-BayHelix China Healthcare Summit) and provides details about the presentation times and links. This is a notification about future corporate activity and investor engagement, rather than a formal financial report (like 10-K, IR, ER) or a specific regulatory filing like a Director's Dealing or Dividend Notice. Since it is a general announcement distributed via RNS (London Stock Exchange's news service), and it doesn't fit the specific categories like AGM-R, CT, or DIV, the most appropriate classification is the general regulatory announcement category, RNS, or potentially RPA if it were announcing the publication of a report, but here it announces participation in external events. Given the context of being distributed via RNS and being a general update, RNS is the best fit, although RPA could also be considered if the announcement itself is viewed as the 'publication' of the event schedule. However, RNS is the designated category for general regulatory announcements distributed through that service.
2018-11-12 English
Scancell to present at Proactive Investors Forum
Report Publication Announcement Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange, which is a primary indicator of a regulatory announcement. The content announces that Scancell Holdings Plc will be presenting at an investor forum ('Proactive Investors One2One Investor Forum') and provides details about the presentation and the company's pipeline. This is not a full financial report (like 10-K or IR), nor is it a specific announcement like a dividend (DIV) or director dealing (DIRS). Since it is a general regulatory news service announcement that doesn't fit a more specific category, the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (3221 chars), supporting the idea that it is an announcement rather than the full report itself.
2018-11-01 English
Results of AGM
AGM Information Classification · 99% confidence The document explicitly states 'Results of AGM' and confirms that 'all resolutions proposed at the Annual General Meeting were duly passed.' This directly relates to the outcome of an Annual General Meeting. The presence of an RNS Number and the closing statement referencing RNS (Regulatory News Service) indicates it is a regulatory announcement. Since the content is the *result* of the AGM, the most specific code is AGM-R (AGM Information/Results). Although it is an RNS filing, AGM-R is a more precise classification than the general RNS fallback.
2018-10-30 English
Identification of 2nd Moditope Cancer Vaccine
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS stands for Regulatory News Service, which is a general regulatory announcement mechanism. The content is an update on product development (Modi-2 vaccine target identification) and mentions an upcoming AGM presentation, but the primary function of this specific filing is to disseminate material, non-public information via the official regulatory channel. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like ER, IR, or CAP, the most appropriate fallback is RNS.
2018-10-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.